|
MechanismH2 receptor antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date11 Dec 2007 |
100 Clinical Results associated with Hubei Huihai Pharmaceutical Technology Research Institute Co., Ltd.
0 Patents (Medical) associated with Hubei Huihai Pharmaceutical Technology Research Institute Co., Ltd.
100 Deals associated with Hubei Huihai Pharmaceutical Technology Research Institute Co., Ltd.
100 Translational Medicine associated with Hubei Huihai Pharmaceutical Technology Research Institute Co., Ltd.